Triglyceride and Fatty Liver: Causes and Treatment

Triglyceride and fatty liver disease are closely connected: raised triglyceride levels both reflect and actively drive the accumulation of fat within liver cells, creating a cycle that can progress to serious liver damage if left unaddressed. In the UK, metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, affects an estimated one in three adults, many of whom remain undiagnosed. Understanding how triglycerides contribute to liver disease, what symptoms to watch for, and which lifestyle changes and treatments are recommended on the NHS can help you take meaningful steps to protect your liver health.

What is the link between triglycerides and fatty liver disease?

High circulating triglycerides increase the fatty acid burden on the liver, promoting fat accumulation in hepatocytes and contributing to MASLD, with insulin resistance mediating this bidirectional relationship.

Elevated triglycerides and fatty liver disease are closely linked, with high circulating triglyceride levels both reflecting and contributing to the accumulation of fat within liver cells. Triglycerides are a form of fat found in the bloodstream, derived from dietary fat and from excess calories that the liver converts into fat for storage. When triglyceride levels are persistently raised, the liver is exposed to a greater burden of fatty acids, which can accumulate within hepatocytes (liver cells) and lead to a condition known as metabolic dysfunction-associated steatotic liver disease (MASLD), previously called non-alcoholic fatty liver disease (NAFLD). You may still encounter the NAFLD term on some NHS resources, as the newer MASLD terminology is being adopted gradually.

Importantly, MASLD is defined in part by the absence of harmful levels of alcohol consumption. Where significant alcohol intake coexists with metabolic risk factors, the condition is termed metabolic dysfunction-associated steatotic liver disease with increased alcohol intake (MetALD), reflecting a distinct and overlapping aetiology.^[1][2] Excessive alcohol consumption independently raises triglycerides and causes alcoholic fatty liver disease, but this is a separate condition from MASLD.

The relationship between triglycerides and liver fat is bidirectional and is largely mediated by insulin resistance. In insulin-resistant states, the liver increases production of very low-density lipoprotein (VLDL) particles and accelerates de novo lipogenesis, the process by which excess carbohydrates and calories are converted into triglycerides. A liver that is already fatty becomes less efficient at processing lipids, which in turn drives further rises in circulating triglycerides.

Several shared risk factors underpin both conditions, including:

• Obesity, particularly central (abdominal) adiposity

• Type 2 diabetes and prediabetes

• Metabolic syndrome, a cluster of conditions including raised blood pressure, high blood sugar and abnormal cholesterol levels

Fatty liver disease affects a substantial proportion of adults in the UK, with the British Liver Trust estimating that around one in three people may be affected, though many remain undiagnosed.^[16]

How do high triglycerides damage the liver over time?

Toxic lipid intermediates, oxidative stress and inflammation caused by lipid overload can advance fatty liver from simple steatosis to MASH, fibrosis and ultimately cirrhosis over years.

Persistently high triglycerides are associated with a cascade of inflammatory and fibrotic processes that can progress from simple fat accumulation to more serious liver disease. In the early stage, excess fat deposits in liver cells without causing significant inflammation, a state referred to as hepatic steatosis. At this point, the liver retains much of its function and the changes may be reversible with appropriate intervention.

It is worth noting that stored triglycerides within liver cells are relatively inert. The greater harm comes from toxic lipid intermediates, including free fatty acids, diacylglycerols and ceramides, that accumulate when the liver's capacity to process lipids is overwhelmed. This lipotoxicity, combined with oxidative stress and low-grade inflammation, can cause the condition to advance to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). In MASH, liver cells become inflamed and begin to die, triggering the deposition of scar tissue (fibrosis).

Not everyone with hepatic steatosis progresses to MASH or cirrhosis. The risk of progression is higher in people with type 2 diabetes, more severe obesity, older age and certain genetic variants. Over years or decades in those who do progress, fibrosis can lead to cirrhosis, a state of advanced scarring in which the liver's architecture is permanently disrupted.

The mechanisms by which lipid overload causes harm include:

• Lipotoxicity: free fatty acids and toxic lipid intermediates are directly harmful to liver cells at high concentrations

• Oxidative stress: excess fat metabolism generates reactive oxygen species that damage cell membranes and DNA

• Inflammatory signalling: fatty acids activate inflammatory pathways, including those involving cytokines such as tumour necrosis factor-alpha

• Mitochondrial dysfunction: overloaded liver mitochondria become less efficient, further impairing fat metabolism

Cirrhosis carries a risk of liver failure and hepatocellular carcinoma (liver cancer). NICE guidance (NG49) highlights that identifying and managing fatty liver disease early is essential to interrupt this progression before irreversible damage occurs.^[4]

What symptoms should prompt you to see a GP?

Persistent unexplained fatigue, upper right abdominal discomfort or nausea warrant a GP review; jaundice, abdominal swelling or sudden severe abdominal pain require urgent or emergency care.

Fatty liver disease is often silent in its early stages, and most people with simple hepatic steatosis have no symptoms at all. The condition is frequently discovered incidentally during blood tests or an ultrasound scan performed for another reason. It is also important to be aware that liver enzyme levels (ALT and AST) can be normal even when MASLD is present, so a normal blood test result does not exclude the condition. Assessment is therefore guided by risk factors as much as by symptoms.

As the disease progresses, some people develop non-specific symptoms that are easy to attribute to other causes. You should contact your GP if you experience:

• Persistent fatigue that is unexplained and does not improve with rest

• Discomfort or a dull ache in the upper right abdomen, where the liver sits beneath the ribcage

• Unexplained weight loss without changes to diet or activity

• Nausea or a general feeling of being unwell over a prolonged period

If liver disease has progressed to cirrhosis, more serious signs may appear, including jaundice (yellowing of the skin or whites of the eyes), swelling of the abdomen (ascites), swollen ankles, easy bruising, or confusion. These features require prompt medical review. Contact your GP as soon as possible if you notice jaundice or significant abdominal swelling.

People with very high triglyceride levels (typically above 10 mmol/L) are also at risk of acute pancreatitis, which can present as sudden, severe pain in the upper abdomen, often radiating to the back, accompanied by nausea and vomiting.^[17] This is a medical emergency. If you develop sudden, severe abdominal pain, vomit blood, or pass very dark or tarry stools, call 999 or go to your nearest accident and emergency department immediately.

Routine blood tests showing raised liver enzymes (ALT or AST) or a high triglyceride level are also reasons to discuss liver health with your GP, even in the absence of symptoms.

How is fatty liver diagnosed and monitored on the NHS?

NHS diagnosis combines lipid profiles, liver function tests, FIB-4 scoring and abdominal ultrasound, with transient elastography or ELF testing used for further fibrosis assessment where needed.

Fatty liver disease is diagnosed on the NHS through a combination of blood tests, imaging and, in some cases, liver biopsy, with the approach guided by NICE recommendations (NG49) and local integrated care board (ICB) pathways. Initial assessment typically begins in primary care with a lipid profile (which includes triglycerides), liver function tests, fasting glucose or HbA1c, and a body mass index measurement. In UK practice, a non-fasting lipid profile is generally acceptable for most people; a fasting sample may be requested if triglycerides are markedly elevated or if the result will guide specific treatment decisions, in line with NICE and local laboratory guidance.

Before diagnosing MASLD, other causes of abnormal liver tests should be considered and excluded where appropriate, including viral hepatitis, significant alcohol intake, autoimmune liver disease and medicines known to cause hepatic steatosis.

The FIB-4 score, a calculation using age, ALT, AST and platelet count, is widely used in NHS primary care to stratify the risk of significant liver fibrosis. Broadly, a low FIB-4 score (typically below 1.30, though age-specific thresholds apply, with higher cut-offs used in people aged over 65 to reduce false positives) is reassuring, while an intermediate or high score prompts referral for further investigation. Where FIB-4 results are indeterminate, the enhanced liver fibrosis (ELF) test, recommended by NICE (DG34) as a second-line non-invasive assessment, may be used where available.^[5] Referral for liver stiffness measurement using transient elastography (FibroScan) is also used in secondary care to estimate the degree of fibrosis without the need for a biopsy in most cases.

Abdominal ultrasound is commonly used to detect fat in the liver and can identify features of cirrhosis such as a nodular liver surface or splenomegaly. However, ultrasound cannot reliably quantify the degree of fibrosis.

Liver biopsy remains the gold standard for staging fibrosis and confirming MASH, but it carries procedural risks and is reserved for cases where non-invasive tests give inconclusive results or where the diagnosis is uncertain.

Ongoing monitoring in people with established fatty liver disease typically involves repeat FIB-4 scoring and liver function tests at intervals determined by the degree of fibrosis, alongside regular review of triglyceride levels, blood glucose and cardiovascular risk factors. Specific monitoring intervals and referral thresholds are set by local ICB pathways in line with NICE NG49.

Can lowering your triglycerides reverse fatty liver disease?

Reducing triglycerides through lifestyle change or medication can reverse liver fat and early fibrosis; weight loss of 7 to 10 per cent or more is associated with meaningful improvement in liver inflammation.

Lowering triglycerides can contribute meaningfully to reversing fatty liver disease, particularly in its earlier stages, though the extent of improvement depends on how far the disease has progressed. In people with simple hepatic steatosis or early fibrosis, sustained reductions in triglyceride levels, achieved through lifestyle change or medication, are associated with a reduction in liver fat content and, in some cases, regression of fibrosis.

The liver has a remarkable capacity for regeneration and repair when the underlying metabolic drivers are addressed. Evidence from clinical studies and guidelines, including those from the European Association for the Study of the Liver (EASL) and the British Society of Gastroenterology (BSG), indicates that a reduction in body weight of around 5 per cent can reduce liver fat, while losses of 7 to 10 per cent or more are associated with improvement in liver inflammation and fibrosis scores, with the greatest histological benefit seen at weight losses of 10 per cent or above.^[4] Because triglyceride levels fall substantially with weight loss, dietary change and increased physical activity, these interventions address both the lipid abnormality and the liver disease simultaneously.

However, once cirrhosis has developed, the structural scarring is largely irreversible, although halting further progression remains a clinically important goal. This underscores the importance of early identification and intervention.

In terms of pharmacological approaches:

• Fibrates (such as fenofibrate) are licensed in the UK for the treatment of hypertriglyceridaemia and mixed dyslipidaemia.^[7][8] Some evidence suggests a possible modest effect on liver inflammation, but this is exploratory and fibrates are not currently recommended by NICE specifically for fatty liver disease.

• Omega-3 fatty acid preparations licensed for severe hypertriglyceridaemia may also reduce liver fat as a secondary effect, though evidence for a specific liver benefit remains limited.

• Pioglitazone and, in selected adults without diabetes, vitamin E are mentioned in NICE NG49 as options that may be considered by a specialist in people with biopsy-proven MASH.^[4][6] These are used off-label in this context and should only be initiated under specialist supervision.

• GLP-1 receptor agonists, such as semaglutide, have demonstrated reductions in liver fat and MASH activity in clinical trials (including a phase 2 trial published in the New England Journal of Medicine in 2021).^[10] They are not currently licensed in the UK specifically for MASLD or MASH, and any use in this context should be discussed with a specialist.

Any pharmacological treatment should be discussed with a GP or specialist.

Lifestyle changes and treatments recommended in the UK

NICE recommends sustained lifestyle modification as the primary treatment, including a Mediterranean-style diet, reduced refined carbohydrates, alcohol limitation and at least 150 minutes of weekly aerobic activity.

The cornerstone of managing both raised triglycerides and fatty liver disease in the UK is sustained lifestyle modification, as recommended by NICE and supported by NHS guidance. No single pharmacological treatment is currently licensed specifically for MASLD or MASH in the UK, making lifestyle intervention the primary and most evidence-based approach for the majority of patients.

Dietary changes with the strongest evidence include:

• Reducing intake of refined carbohydrates and added sugars, which are potent drivers of hepatic triglyceride synthesis

• Limiting alcohol consumption; the UK Chief Medical Officers advise that to keep health risks from alcohol low, it is safest not to drink more than 14 units per week regularly, and to spread drinking over three or more days if you do drink this amount.^[11] Because MASLD is defined by the absence of harmful alcohol intake, keeping within low-risk limits is particularly important for people with this condition

• Adopting a Mediterranean-style diet, rich in vegetables, legumes, whole grains, fish and olive oil, which has been shown to reduce liver fat

• Avoiding ultra-processed foods and sugar-sweetened beverages

Physical activity is independently beneficial for liver health beyond its effect on weight. UK Chief Medical Officers' guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, alongside muscle-strengthening activities on two or more days per week.^[12][13] Resistance exercise also improves insulin sensitivity and reduces liver fat.

Weight management programmes available through the NHS, including referral to structured behavioural weight management services, can support people who are overweight or obese. For those with a BMI of 35 or above (or 32.5 or above in people of South Asian, Chinese, Black African or Black Caribbean family background) and relevant comorbidities, NICE has appraised certain weight management medicines, including semaglutide (Wegovy) and tirzepatide (Mounjaro), that may be considered by a clinician. Access depends on local ICB commissioning decisions and individual clinical eligibility.

Statins are safe to use in people with MASLD and should not be stopped solely because of mildly elevated liver enzymes. They are indicated for cardiovascular risk reduction, which is an important consideration given the elevated cardiometabolic risk associated with fatty liver disease and hypertriglyceridaemia. Any decision about statin use should be made with your GP or specialist.

Smoking cessation and management of blood pressure and blood glucose are also integral to reducing overall cardiometabolic risk in people with fatty liver disease and hypertriglyceridaemia.

For people exploring weight management options, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online consultations with prescriber review and pharmacist support, where clinically appropriate treatment options may be considered.

Suspected adverse effects of any prescribed medicine should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
2. Understanding the evolving nomenclature of steatotic liver disease.
3. Hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease (MetALD).
4. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management. NG49.
5. MRI-based technologies for assessing non-alcoholic fatty liver disease: The diagnostic tests (HTG655, referencing DG34 ELF test recommendation).
6. GID-TA11477 draft scope post-referral: pioglitazone or vitamin E in NAFLD/MASH.
7. Fenofibrate – British National Formulary.
8. Fibrates: first-line treatment not recommended.
9. Fenofibrate 160mg Tablets – Summary of Product Characteristics.
10. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis (Newsome PN et al.).
11. Alcohol consumption: advice on low risk drinking – UK Chief Medical Officers.
12. Physical activity guidelines: UK Chief Medical Officers' report.
13. Physical activity guidelines for adults aged 19 to 64.
14. Semaglutide for managing overweight and obesity (TA875).
15. Tirzepatide for managing overweight and obesity (TA1026).
16. Liver disease: applying All Our Health.
17. Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis (Pedersen SB et al.).

Frequently Asked Questions